5-α Reductase Inhibitors Class Overview Monograph

Mechanism of Action

5-α reductase inhibitors work by competitively binding and inhibiting the 5-α reductase enzyme, which converts testosterone into the more potent androgen dihydrotestosterone (DHT). DHT is the dominant androgen in prostate tissue and in hair follicles of the scalp vertex, and its reduction forms the pharmacologic basis for treating both BPH and androgenetic alopecia.

Isoenzyme Selectivity

Three isoforms of 5-α reductase have been identified. Type I predominates in sebaceous glands, liver, and skin. Type II predominates in the prostate, seminal vesicles, epididymis, and hair follicles. Type III was identified later in brain and peripheral tissues, though its clinical significance remains under investigation 1.

Finasteride selectively inhibits the Type II isoenzyme. Dutasteride is a dual inhibitor, blocking both Type I and Type II isoenzymes. This difference in selectivity accounts for the greater DHT suppression seen with dutasteride: serum DHT falls by approximately 70 percent with finasteride 5 mg daily and by over 90 percent with dutasteride 0.5 mg daily 2.

Intraprostatic Androgen Reduction

Within the prostate, Type II predominance means both agents reduce intraprostatic DHT concentrations. A pharmacokinetic study in men undergoing prostatectomy found dutasteride reduced intraprostatic DHT by 94 percent compared with 85 percent for finasteride, though the clinical significance of this difference in BPH symptom outcomes remains debated 3.

Pharmacokinetics

The two agents diverge significantly in absorption, metabolism, and elimination, and these differences influence prescribing decisions around washout periods, drug interactions, and clinical onset.

Finasteride

Finasteride is well absorbed orally with a bioavailability of approximately 63 percent. It is not affected meaningfully by food. Peak plasma concentrations occur at 1 to 2 hours. The drug is extensively metabolized by hepatic CYP3A4 (with minor CYP3A5 contribution) to inactive metabolites. Its terminal half-life is 6 to 8 hours in men aged 18 to 60, extending to roughly 8 hours in men over 70. Steady-state is reached within days. Excretion occurs via both feces (57 percent) and urine (39 percent) 4.

Dutasteride

Dutasteride reaches peak plasma concentration in 2 to 3 hours. Bioavailability is approximately 60 percent and is not clinically altered by food. The drug is metabolized by CYP3A4 and CYP3A5 to active and inactive metabolites. Its half-life is strikingly long: approximately 5 weeks at steady state. Serum concentrations remain detectable for 4 to 6 months after discontinuation. This prolonged half-life means steady-state is not reached for approximately 6 months. Excretion is primarily fecal 5.

The long half-life of dutasteride carries practical implications. Washout before a PSA-based prostate cancer screening requires months, not weeks. Women of childbearing potential should avoid handling crushed or broken dutasteride capsules, and men taking dutasteride should not donate blood until at least 6 months after the last dose.

FDA-Approved Indications and Dosing

Both agents are approved for BPH. Only finasteride carries an FDA-approved indication for androgenetic alopecia, though dutasteride is used off-label for hair loss in several countries and has regulatory approval for AGA in Japan and South Korea 6.

BPH Dosing

Finasteride is dosed at 5 mg once daily (Proscar) for BPH. Dutasteride is dosed at 0.5 mg once daily (Avodart). Both can be taken without regard to meals. Symptom improvement is gradual: the AUA/SUFU guideline notes clinicians should counsel patients that a minimum trial of 6 to 12 months is needed to assess benefit, and that discontinuation leads to symptom recurrence within months 7.

AGA Dosing

Finasteride 1 mg once daily (Propecia) is approved for male pattern hair loss. The Phase III trials that supported approval enrolled men aged 18 to 41 with mild-to-moderate vertex hair loss. At 2 years, 83 percent of men on finasteride 1 mg maintained or increased hair count versus 28 percent on placebo 8. Hair regrowth peaks at 1 to 2 years, and continued treatment is needed to maintain results.

Landmark Clinical Trials

PLESS (Proscar Long-Term Efficacy and Safety Study)

This 4-year, randomized, double-blind trial (N=3,040) compared finasteride 5 mg to placebo in men with moderate-to-severe BPH symptoms. Finasteride reduced the risk of acute urinary retention by 57 percent and the risk of BPH-related surgery by 55 percent. Prostate volume decreased by a mean of 18 percent with finasteride versus a 14 percent increase with placebo 9.

MTOPS (Medical Therapy of Prostatic Symptoms)

MTOPS (N=3,047) compared finasteride alone, doxazosin alone, combination therapy, and placebo over a mean follow-up of 4.5 years. Combination therapy reduced overall clinical progression of BPH by 66 percent relative to placebo, outperforming either monotherapy. The study established combination α-blocker plus 5-α reductase inhibitor therapy as a standard for men with larger prostates 10.

CombAT (Combination of Avodart and Tamsulosin)

CombAT (N=4,844) evaluated dutasteride plus tamsulosin versus each agent alone over 4 years. Combination therapy reduced the relative risk of acute urinary retention or BPH-related surgery by 65.8 percent versus tamsulosin alone. By year 2, combination therapy was superior to tamsulosin monotherapy on all symptomatic endpoints 11.

PCPT (Prostate Cancer Prevention Trial)

PCPT (N=18,882) tested whether finasteride 5 mg daily could prevent prostate cancer over 7 years. Finasteride reduced the period prevalence of prostate cancer by 24.8 percent (18.4 percent vs. 24.4 percent for placebo). A secondary finding caused concern: among men who did develop cancer, higher-grade tumors (Gleason 7 to 10) were more frequent in the finasteride group (6.4 percent vs. 5.1 percent). Subsequent long-term analyses with 18 years of follow-up showed no significant difference in overall survival between groups, and the FDA label was not updated to include a cancer prevention indication 12.

REDUCE Trial

REDUCE (N=8,231) examined dutasteride 0.5 mg daily for prostate cancer risk reduction over 4 years. Dutasteride reduced the relative risk of biopsy-detectable prostate cancer by 22.8 percent (659 cancers in the dutasteride group vs. 858 in the placebo group). As in PCPT, a small increase in higher-grade tumors (Gleason 8 to 10) was observed in the dutasteride arm, though whether this reflects detection bias from smaller prostates improving biopsy sensitivity remains debated 13.

Adverse Effects and Safety

Sexual Side Effects

The most frequently reported adverse effects are sexual in nature. In the PLESS trial, drug-related sexual adverse events occurred in 15.8 percent of finasteride-treated men vs. 7.7 percent on placebo over 4 years. Specific rates included decreased libido (6.4 percent vs. 3.4 percent), erectile dysfunction (8.1 percent vs. 3.7 percent), and decreased ejaculate volume (3.7 percent vs. 0.8 percent) 9. For the 1 mg AGA dose, reported sexual adverse event rates are lower (1.3 to 3.8 percent) and most resolve upon discontinuation or with continued use.

The Endocrine Society's 2018 statement notes: "Most men who experience sexual side effects on finasteride or dutasteride find that symptoms resolve after drug discontinuation. A small subset reports persistent symptoms, though controlled data on persistent post-finasteride syndrome remain limited" 14.

PSA Interpretation

Both agents reduce serum PSA by approximately 50 percent after 6 months of treatment. The AUA guideline states: "PSA values should be doubled in men taking a 5-alpha reductase inhibitor to approximate the unmedicated PSA for prostate cancer screening purposes. Any confirmed rise in PSA while on a 5ARI should prompt evaluation" 7.

Failure to apply this correction risks missing clinically significant prostate cancer. A sustained rise in PSA during 5-ARI therapy should be investigated regardless of the absolute value.

Gynecomastia and Breast Tenderness

Breast tenderness or gynecomastia is reported in 1 to 2 percent of patients. It typically resolves with discontinuation but may persist in rare cases.

Mood and Neuropsychiatric Effects

Post-marketing reports and pharmacovigilance data have identified depression, anxiety, and suicidal ideation as potential signals. The FDA added mood-related adverse events to the finasteride and dutasteride labels in 2012. A retrospective cohort study (N=93,197 men on 5-ARIs) found a small but statistically significant increase in self-harm events during the initial 18 months of exposure (HR 1.88, 95% CI 1.34 to 2.64), with attenuation beyond 18 months 15. Clinicians should screen for depressive symptoms at follow-up visits, particularly in the first year.

Drug Interactions

Significant pharmacokinetic drug interactions are uncommon. Both agents are CYP3A4 substrates, so strong CYP3A4 inhibitors (ketoconazole, ritonavir, clarithromycin) may increase exposure. In practice, no formal dose adjustments are recommended by the FDA labels, but co-prescription with potent CYP3A4 inhibitors warrants monitoring, particularly for dutasteride given its prolonged half-life 5.

Interaction with α-Blockers

5-ARIs are frequently co-prescribed with α-adrenergic blockers (tamsulosin, doxazosin, alfuzosin). No pharmacokinetic interactions have been identified. As MTOPS and CombAT demonstrated, combination therapy is safe and more effective than monotherapy for men with larger prostates and moderate-to-severe symptoms 10.

Interaction with Testosterone Replacement

In men receiving exogenous testosterone, 5-ARIs reduce conversion to DHT but do not block the androgenic effects of testosterone itself. This combination is sometimes used clinically to mitigate DHT-mediated side effects of TRT (acne, hair loss, prostate growth) while maintaining testosterone's anabolic and mood benefits. No controlled trials have evaluated long-term outcomes of this combination.

Special Populations

Hepatic Impairment

Finasteride pharmacokinetics have not been studied in hepatic impairment; the label advises caution. Dutasteride has also not been formally studied in this population. Given hepatic CYP3A4 metabolism, dose reduction or avoidance should be considered in severe hepatic dysfunction.

Renal Impairment

No dose adjustment is necessary for either agent in renal impairment. Minimal renal excretion of parent drug makes accumulation unlikely even in advanced CKD 4.

Women and Children

5-ARIs are classified as Category X. DHT is essential for normal male fetal genital development. Exposure during pregnancy can cause external genital abnormalities in male fetuses. Women of childbearing potential must not handle crushed or broken tablets/capsules. Finasteride and dutasteride are not approved for use in pediatric patients.

Older Adults

No dose adjustment is required based on age alone. In the PLESS cohort, men over 70 showed comparable efficacy and adverse effect rates to younger cohorts, though the extended finasteride half-life in this group (approximately 8 hours vs. 6 hours) is not considered clinically meaningful 9.

Monitoring Recommendations

A structured monitoring approach ensures accurate cancer screening and early detection of adverse effects.

Baseline

Before initiation, obtain a PSA, digital rectal examination (DRE), assessment of BPH symptom severity (IPSS/AUA-SI), and a baseline assessment of sexual function and mood. For AGA patients, a baseline scalp photograph aids in tracking response.

Ongoing

Recheck PSA at 3 to 6 months to establish the new suppressed baseline. Subsequent PSA values should be doubled for screening interpretation. Any confirmed rise above the post-treatment nadir warrants urologic referral. Screen for sexual dysfunction and depressive symptoms at each follow-up, particularly during the first 12 months. For BPH patients, repeat IPSS at 6 and 12 months to assess response.

Discontinuation

After stopping finasteride, DHT levels normalize within 2 weeks. After stopping dutasteride, normalization may take 4 to 6 months due to the prolonged half-life. PSA values return to pre-treatment levels over the same timeframes. Patients should be counseled that BPH symptoms will recur and hair loss will resume upon discontinuation.

Finasteride vs. Dutasteride: Choosing Between Agents

Head-to-head data comparing finasteride 5 mg and dutasteride 0.5 mg for BPH are limited. The EPICS trial (N=1,630) found no statistically significant difference in IPSS change at 12 months between the two agents 16. Dutasteride's greater DHT suppression has not clearly translated into superior clinical outcomes for BPH in comparative trials.

For androgenetic alopecia, a randomized 24-week trial (N=416) comparing dutasteride 0.5 mg to finasteride 1 mg found dutasteride superior in hair count increase at the vertex (target area hair count difference of 12.2 hairs/cm² favoring dutasteride), though both agents were well tolerated 17.

Practical considerations often drive agent selection. Finasteride is available as a low-cost generic, offers a shorter half-life (allowing faster washout if adverse effects arise), and has the only FDA-approved AGA indication. Dutasteride may be preferred in men with very large prostates or suboptimal response to finasteride, and in countries where dutasteride carries an AGA indication.